Viatris Inc. (VTRS) Stock

Healthcare · Drug Manufacturers - Specialty & Generic · Member of S&P 500

Viatris Inc. (VTRS) closed at USD 17.44 on 2026-10-14, a change of +75.5 % over the past year, with a market capitalization of USD 20.93B.

Viatris Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Viatris Inc. key figures

Previous close

USD 17.44 (2026-10-14)

1-year change

+75.5 %

Market cap

USD 20.93B

Enterprise value

USD 33.04B

P/E ratio (trailing)

-47.95

P/E ratio (forward)

6.79

EPS (trailing)

-0.38

EPS (forward)

2.68

PEG ratio

3.17

Price to book

1.48

Revenue growth

4.9 %

Earnings growth

n/a

Dividend per share (trailing)

0.48

Short ratio

4.65

Employees

30,000

Analyst consensus (third-party)

buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Viatris Inc.

Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East. It operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The company offers prescription brand drugs, generic drugs, complex generic drugs, and biosimilars. It also provides drugs in various therapeutic areas covering various noncommunicable and infectious diseases, including cardiovascular, CNS and anesthesia, dermatology, diabetes and metabolism, eye care, gastroenterology, immunology, oncology, and respiratory and allergy, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. In addition, the company offers medicines in the form of oral solid doses, injectables, and complex dosage forms to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. It distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies under the Lyrica, Lipitor, Celebrex, Viagra, Creon, Influvac, Wixela Inhub, EpiPen Auto-Injector, Fraxiparine, Yupelri, Norvasc, Amitiza, Effexor, Lipacreon, Zoloft, Xalabrands, Dymista, Xanax, and Breyna brands. The company has collaboration agreements with Mapi Pharma Ltd. to develop and commercialize long-acting glatiramer acetate depot products and additional products; Revance Therapeutics, Inc. to develop, manufacture, and commercialize a biosimilar to the branded biologic product, BOTOX; and Theravance Biopharma, Inc. to develop and commercialize revefenacin. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Viatris Inc. and compare it with other stocks.